Jane Bell joins Mesoblast Board as Independent Director

Australia-based Mesoblast, a global leader in allogeneic cellular medicines for inflammatory diseases, has appointed Jane Bell to its Board of Directors. Jane is a banking and finance lawyer with 22 years of corporate finance expertise focussing on international investment transactions in the United States, Canada, Australia and the United Kingdom, including funds management, mergers, acquisitions, and divestments. She has served as a non-executive Director in a diverse range of highly regulated sectors including delivery of healthcare, life sciences, medical research, and funds management. Jane currently serves as Deputy Chair of Monash Health, one of Australia’s largest and most diverse public health services delivering more than 3.46 million episodes of care across an extensive network of hospitals, rehabilitation, aged care, community health and mental health facilities and a former Chair of Melbourne Health. From 2014 until 2021 she was a director of U Ethical, Australia’s first ethical funds manager with over $1.2 billion of funds under management, and a member of its Investment Committee.